The second gene chosen as experimental target was CA9, a gene already considered a promising target in breast [29,30,31], lung [32,33], colon [34,35], and bladder [36] carcinomas, and in medulloblastomas and glioblastomas [37,38,39]. Here, CA9 is linked to carcinoma.